Skip to main content

Advertisement

SpringerLink
Log in

Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides

  • B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Armitage, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Cutaneous lymphomas (CL) are a heterogeneous group of neoplasms characterized with clinical and histopathological variation, as well as overlap with benign dermatoses. Diagnosis and treatment of CLs is challenging and often requires a multidisciplinary approach. However, prognostic knowledge of these conditions and awareness of treatment options can help optimize appropriate use of available regimens, thereby improving care for patients. Here, we review the most recent literature and outline treatment themes for managing patients with cutaneous B-cell and T-cell lymphomas other than mycosis fungoides.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–85.

    Article  CAS  PubMed  Google Scholar 

  2. Morales AV, Arber DA, Seo K, Kohler S, Kim YH, Sundram UN. Evaluation of B-cell clonality using the BIOMED-2 PCR method effectively distinguishes cutaneous B-cell lymphoma from benign lymphoid infiltrates. Am J Dermatopathol. 2008;30(5):425–30.

    Article  PubMed  Google Scholar 

  3. Fujiwara M, Morales AV, Seo K, Kim YH, Arber DA, Sundram UN. Clonal identity and differences in primary cutaneous B-cell lymphoma occurring at different sites or time points in the same patient. Am J Dermatopathol. 2013;35(1):11–8.

  4. Nihal M, Mikkola D, Wood GS. Detection of clonally restricted immunoglobulin heavy chain gene rearrangements in normal and lesional skin: analysis of the B cell component of the skin-associated lymphoid tissue and implications for the molecular diagnosis of cutaneous B cell lymphomas. J Mol Diagn. 2000;2(1):5–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Kadin M, Nasu K, Sako D, Said J, Vonderheid E. Lymphomatoid papulosis. A cutaneous proliferation of activated helper T cells expressing Hodgkin's disease-associated antigens. Am J Pathol. 1985;119(2):315–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000;95(12):3653–61.

    CAS  PubMed  Google Scholar 

  7. Kunishige JH, McDonald H, Alvarez G, Johnson M, Prieto V, Duvic M. Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients. Clin Exp Dermatol. 2009;34(5):576–81.

    Article  CAS  PubMed  Google Scholar 

  8. Wieser I, Oh CW, Talpur R, Duvic M. Lymphomatoid papulosis: treatment response and associated lymphomas in a study of 180 patients. J Am Acad Dermatol. 2016;74(1):59–67.

    Article  PubMed  Google Scholar 

  9. Wolf P, Cerroni L, Smolle J, Kerl H. PUVA-induced lymphomatoid papulosis in a patient with mycosis fungoides. J Am Acad Dermatol. 1991;25(2):422–6.

    Article  CAS  PubMed  Google Scholar 

  10. Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol. 1996;34(3):470–81.

    Article  CAS  PubMed  Google Scholar 

  11. Krathen RA, Ward S, Duvic M. Bexarotene is a new treatment option for lymphomatoid papulosis. Dermatology. 2003;206(2):142–7.

    Article  CAS  PubMed  Google Scholar 

  12. Duvic M, Tetzlaff MT, Gangar P, et al. Results of a phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33(32):3759–65.

    Article  CAS  PubMed  Google Scholar 

  13. Willemze R, Beljaards RC. Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders. A proposal for classification and guidelines for management and treatment. J Am Acad Dermatol. 1993;28(6):973–80.

    Article  CAS  PubMed  Google Scholar 

  14. Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 2003;49(6):1049–58.

    Article  PubMed  Google Scholar 

  15. Woo DK, Jones CR, Vanoli-Storz MN, et al. Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Arch Dermatol. 2009;145(6):667–74.

    Article  PubMed  Google Scholar 

  16. Parrilla Castillar ER, Jaffe ES, Said J, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124:1473–80.

    Article  CAS  Google Scholar 

  17. Feldman AL, Law M, Remstein ED, et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia. 2009;23:574–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Karai LJ, Kadin ME, Hsi ED, et al. Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. Am J Surg Pathol. 2013;37:1173–81.

    Article  PubMed  Google Scholar 

  19. Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011;118(15):4024–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012;119(18):4115–22.

    Article  CAS  PubMed  Google Scholar 

  21. Gallardo F, Pujol RM. Subcutaneous panniculitic-like T-cell lymphoma and other primary cutaneous lymphomas with prominent subcutaneous tissue involvement. Dermatol Clin. 2008;26(4):529–40. viii.

    Article  PubMed  Google Scholar 

  22. Takeshita M, Okamura S, Oshiro Y, et al. Clinicopathologic differences between 22 cases of CD56-negative and CD56-positive subcutaneous panniculitis-like lymphoma in Japan. Hum Pathol. 2004;35(2):231–9.

    Article  PubMed  Google Scholar 

  23. Paulli M, Berti E. Cutaneous T-cell lymphomas (including rare subtypes). Current concepts. II. Haematologica. 2004;89(11):1372–88.

    PubMed  Google Scholar 

  24. Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, Group EGW. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol : Off J Eur Soc Med Oncol / ESMO. 2013;24 Suppl 6:vi149–54.

    Article  Google Scholar 

  25. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Vol 2. Lyon, France: International Agency for Research on Cancer; 2008.

  26. Go RS, Wester SM. Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma: a systematic analysis of 156 patients reported in the literature. Cancer. 2004;101(6):1404–13.

    Article  PubMed  Google Scholar 

  27. Matsue K, Itoh M, Tsukuda K, Miyazaki K, Kokubo T. Successful treatment of cytophagic histiocytic panniculitis with modified CHOP-E. Cyclophosphamide, adriamycin, vincristine, predonisone, and etoposide. Am J Clin Oncol. 1994;17(6):470–4.

    Article  CAS  PubMed  Google Scholar 

  28. Perez-Persona E, Mateos-Mazon JJ, Lopez-Villar O, et al. Complete remission of subcutaneous panniculitic T-cell lymphoma after allogeneic transplantation. Bone Marrow Transplant. 2006;38(12):821–2.

    Article  CAS  PubMed  Google Scholar 

  29. Ichii M, Hatanaka K, Imakita M, Ueda Y, Kishino B, Tamaki T. Successful treatment of refractory subcutaneous panniculitis-like T-cell lymphoma with allogeneic peripheral blood stem cell transplantation from HLA-mismatched sibling donor. Leuk lymphoma. 2006;47(10):2250–2.

    Article  PubMed  Google Scholar 

  30. Yuan L, Sun L, Bo J, et al. Durable remission in a patient with refractory subcutaneous panniculitis-like T-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation through withdrawal of cyclosporine. Annal Transplant : Q Pol Transplant Soc. 2011;16(3):135–8.

    Article  CAS  Google Scholar 

  31. Mukai HY, Okoshi Y, Shimizu S, et al. Successful treatment of a patient with subcutaneous panniculitis-like T-cell lymphoma with high-dose chemotherapy and total body irradiation. Eur J Haematol. 2003;70(6):413–6.

    Article  PubMed  Google Scholar 

  32. Mehta N, Wayne AS, Kim YH, et al. Bexarotene is active against subcutaneous panniculitis-like T-cell lymphoma in adult and pediatric populations. Clin Lymphoma Myeloma Leuk. 2012;12(1):20–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Wang CY, Su WP, Kurtin PJ. Subcutaneous panniculitic T-cell lymphoma. Int J Dermatol. 1996;35(1):1–8.

    Article  CAS  PubMed  Google Scholar 

  34. Papenfuss JS, Aoun P, Bierman PJ, Armitage JO. Subcutaneous panniculitis-like T-cell lymphoma: presentation of 2 cases and observations. Clin lymphoma. 2002;3(3):175–80.

    Article  PubMed  Google Scholar 

  35. Springinsfeld G, Guillaume JC, Boeckler P, Tortel MC, Cribier B. Two cases of subcutaneous panniculitis-like T-cell lymphoma (CD4- CD8+ CD56-). Ann Dermatol Venereol. 2009;136(3):264–8.

    Article  CAS  PubMed  Google Scholar 

  36. Jung HR, Yun SY, Choi JH, Bae SH, Ryoo HM, Kum YS. Cyclosporine in Relapsed Subcutaneous Panniculitis-like T-Cell Lymphoma after Autologous Hematopoietic Stem Cell Transplantation. Cancer Res Treat : Off J Korean Cancer Assoc. 2011;43(4):255–9.

    Article  Google Scholar 

  37. Lee WS, Hwang JH, Kim MJ, et al. Cyclosporine A as a primary treatment for panniculitis-like T cell lymphoma: a case with a long-term remission. Cancer Res Treat : Off J Korean Cancer Assoc. 2014;46(3):312–6.

    Article  CAS  Google Scholar 

  38. Hathaway T, Subtil A, Kuo P, Foss F. Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-cell lymphoma. Clin Lymphoma Myeloma. 2007;7(8):541–5.

    Article  CAS  PubMed  Google Scholar 

  39. Guitart J, Weisenburger DD, Subtil A, et al. Cutaneous gammadelta T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. Am J Surg Pathol. 2012;36(11):1656–65.

    Article  PubMed  Google Scholar 

  40. Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood. 2003;101(9):3407–12.

    Article  CAS  PubMed  Google Scholar 

  41. Takahashi Y, Takata K, Kato S, et al. Clinicopathological analysis of 17 primary cutaneous T-cell lymphoma of the gammadelta phenotype from Japan. Cancer Sci. 2014;105(7):912–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Garcia-Herrera A, Song JY, Chuang SS, et al. Nonhepatosplenic gammadelta T-cell lymphomas represent a spectrum of aggressive cytotoxic T-cell lymphomas with a mainly extranodal presentation. Am J Surg Pathol. 2011;35(8):1214–25.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Magro CM, Wang X. Indolent primary cutaneous gamma/delta T-cell lymphoma localized to the subcutaneous panniculus and its association with atypical lymphocytic lobular panniculitis. Am J Clin Pathol. 2012;138(1):50–6.

    Article  PubMed  Google Scholar 

  44. Nofal A, Abdel-Mawla MY, Assaf M, Salah E. Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma: proposed diagnostic criteria and therapeutic evaluation. J Am Acad Dermatol. 2012;67(4):748–59.

    Article  PubMed  Google Scholar 

  45. Robson A, Assaf C, Bagot M, et al. Aggressive epidermotropic cutaneous CD8+ lymphoma: a cutaneous lymphoma with distinct clinical and pathological features. Report of an EORTC Cutaneous Lymphoma Task Force Workshop. Histopathology. 2015;67(4):425–41.

    Article  PubMed  Google Scholar 

  46. Berti E, Tomasini D, Vermeer MH, Meijer CJ, Alessi E, Willemze R. Primary cutaneous CD8-positive epidermotropic cytotoxic T-cell lymphomas: a distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol. 1999;155:483–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Beltraminelli H, Mullegger R, Cerroni L. Indolent CD8+ lymphoid proliferation of the ear: a phenotypic variant of the small-medium pleomorphic cutaneous T-cell lymphoma? J Cutan Pathol. 2010;37(1):81–4.

    Article  PubMed  Google Scholar 

  48. Swick BL, Baum CL, Venkat AP, Liu V. Indolent CD8+ lymphoid proliferation of the ear: report of two cases and review of the literature. J Cutan Pathol. 2011;38(2):209–15.

    Article  PubMed  Google Scholar 

  49. Gormley RH, Hess SD, Anand D, Junkins-Hopkins J, Rook AH, Kim EJ. Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma. J Am Acad Dermatol. 2010;62(2):300–7.

    Article  PubMed  Google Scholar 

  50. James E, Sokhn JG, Gibson JF, et al. CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature. Leuk lymphoma. 2015;56(4):951–7.

    Article  CAS  PubMed  Google Scholar 

  51. Rodriguez Pinilla SM, Roncador G, Rodriguez-Peralto JL, et al. Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers. Am J Surg Pathol. 2009;33(1):81–90.

    Article  PubMed  Google Scholar 

  52. Beltraminelli H, Leinweber B, Kerl H, Cerroni L. Primary cutaneous CD4+ small-/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases. Am J Dermatopathol. 2009;31(4):317–22.

    Article  PubMed  Google Scholar 

  53. Bekkenk MW, Vermeer MH, Jansen PM, et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood. 2003;102(6):2213–9.

    Article  CAS  PubMed  Google Scholar 

  54. Grogg KL, Jung S, Erickson LA, McClure RF, Dogan A. Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior. Mod Pathol : Off J U S Can Acad Pathol Inc. 2008;21(6):708–15.

    Article  CAS  Google Scholar 

  55. Williams VL, Torres-Cabala CA, Duvic M. Primary cutaneous small- to medium-sized CD4+ pleomorphic T-cell lymphoma: a retrospective case series and review of the provisional cutaneous lymphoma category. Am J Clin Dermatol. 2011;12(6):389–401.

    Article  PubMed  Google Scholar 

  56. Baum CL, Link BK, Neppalli VT, Swick BL, Liu V. Reappraisal of the provisional entity primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoma: a series of 10 adult and pediatric patients and review of the literature. J Am Acad Dermatol. 2011;65(4):739–48.

    Article  PubMed  Google Scholar 

  57. Suchak R, O’Connor S, McNamara C, Robson A. Indolent CD8-positive lymphoid proliferation on the face: part of the spectrum of primary cutaneous small-/medium-sized pleomorphic T-cell lymphoma or a distinct entity? J Cutan Pathol. 2010;37(9):977–81.

    Article  PubMed  Google Scholar 

  58. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Dummer R, Asagoe K, Cozzio A, et al. Recent advances in cutaneous lymphomas. J Dermatol Sci. 2007;48(3):157–67.

    Article  CAS  PubMed  Google Scholar 

  60. Senff NJ, Hoefnagel JJ, Jansen PM, et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J Clin Oncol : Off J Am Soc Clin Oncol. 2007;25(12):1581–7.

    Article  Google Scholar 

  61. Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(2):479–84.

    Article  CAS  PubMed  Google Scholar 

  62. Hoefnagel JJ, Vermeer MH, Jansen PM, et al. Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases. Arch Dermatol. 2005;141(9):1139–45.

    Article  CAS  PubMed  Google Scholar 

  63. Zendri E, Venturi C, Ricci R, Giordano G, De Panfilis G. Primary cutaneous plasmacytoma: a role for a triggering stimulus? Clin Exp Dermatol. 2005;30(3):229–31.

    Article  CAS  PubMed  Google Scholar 

  64. May SA, Netto G, Domiati-Saad R, Kasper C. Cutaneous lymphoid hyperplasia and marginal zone B-cell lymphoma following vaccination. J Am Acad Dermatol. 2005;53(3):512–6.

    Article  PubMed  Google Scholar 

  65. Aberer E, Fingerle V, Wutte N, Fink-Puches R, Cerroni L. Within European margins. Lancet. 2011;377(9760):178.

    Article  PubMed  Google Scholar 

  66. Cerroni L, Zochling N, Putz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol. 1997;24(8):457–61.

    Article  CAS  PubMed  Google Scholar 

  67. Goodlad JR, Davidson MM, Hollowood K, et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland. Am J Surg Pathol. 2000;24(9):1279–85.

    Article  CAS  PubMed  Google Scholar 

  68. Ponzoni M, Ferreri AJ, Mappa S, et al. Prevalence of Borrelia burgdorferi infection in a series of 98 primary cutaneous lymphomas. Oncologist. 2011;16(11):1582–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Wood GS, Kamath NV, Guitart J, et al. Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States. J Cutan Pathol. 2001;28(10):502–7.

    Article  CAS  PubMed  Google Scholar 

  70. Servitje O, Gallardo F, Estrach T, et al. Primary cutaneous marginal zone B-cell lymphoma: a clinical, histopathological, immunophenotypic and molecular genetic study of 22 cases. Br J Dermatol. 2002;147(6):1147–58.

    Article  CAS  PubMed  Google Scholar 

  71. Edinger JT, Kant JA, Swerdlow SH. Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets. Am J Surg Pathol. 2010;34(12):1830–41.

    Article  PubMed  Google Scholar 

  72. Cho-Vega JH, Vega F, Rassidakis G, Medeiros LJ. Primary cutaneous marginal zone B-cell lymphoma. Am J Clin Pathol. 2006;125(Suppl):S38–49.

    PubMed  Google Scholar 

  73. Xie X, Sundram U, Natkunam Y, et al. Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma. Mod Pathol. 2008;21(6):653–9.

    Article  CAS  PubMed  Google Scholar 

  74. Mirza I, Macpherson N, Paproski S, et al. Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features. J Clin Oncol. 2002;20(3):647–55.

    Article  CAS  PubMed  Google Scholar 

  75. Grange F, Beylot-Barry M, Courville P, et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch Dermatol. 2007;143(9):1144–50.

    Article  PubMed  Google Scholar 

  76. Vermeer MH, Geelen FA, van Haselen CW, et al. Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group [see comments]. Arch Dermatol. 1996;132(11):1304–8.

    Article  CAS  PubMed  Google Scholar 

  77. Geelen FA, Vermeer MH, Meijer CJ, et al. bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related. J Clin Oncol. 1998;16(6):2080–5.

    CAS  PubMed  Google Scholar 

  78. Grange F, Petrella T, Beylot-Barry M, et al. Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas. Blood. 2004;103(10):3662–8.

    Article  CAS  PubMed  Google Scholar 

  79. Hoefnagel JJ, Vermeer MH, Jansen PM, Fleuren GJ, Meijer CJ, Willemze R. Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance. Br J Dermatol. 2003;149(6):1183–91.

    Article  CAS  PubMed  Google Scholar 

  80. Sundram U, Kim Y, Mraz-Gernhard S, Hoppe R, Natkunam Y, Kohler S. Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study. J Cutan Pathol. 2005;32(3):227–34.

    Article  PubMed  Google Scholar 

  81. Streubel B, Simonitsch-Klupp I, Mullauer L, et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia. 2004;18(10):1722–6.

    Article  CAS  PubMed  Google Scholar 

  82. Streubel B, Scheucher B, Valencak J, et al. Molecular cytogenetic evidence of t(14;18)(IGH;BCL2) in a substantial proportion of primary cutaneous follicle center lymphomas. Am J Surg Pathol. 2006;30(4):529–36.

    Article  PubMed  Google Scholar 

  83. Cerroni L, Arzberger E, Putz B, et al. Primary cutaneous follicle center cell lymphoma with follicular growth pattern. Blood. 2000;95(12):3922–8.

    CAS  PubMed  Google Scholar 

  84. Hoefnagel JJ, Dijkman R, Basso K, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005;105(9):3671–8.

  85. Dijkman R, Tensen CP, Jordanova ES, et al. Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma. J Clin Oncol. 2006;24(2):296–305.

    Article  CAS  PubMed  Google Scholar 

  86. Hallermann C, Kaune KM, Gesk S, et al. Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas. J Investig Dermatol. 2004;123(1):213–9.

    Article  CAS  PubMed  Google Scholar 

  87. NCCN guidelines. http://www.nccn.org.

  88. Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008;112(5):1600–9.

    Article  CAS  PubMed  Google Scholar 

  89. Neelis KJ, Schimmel EC, Vermeer MH, Senff NJ, Willemze R, Noordijk EM. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys. 2009;74(1):154–8.

    Article  PubMed  Google Scholar 

  90. Cozzio A, Kempf W, Schmid-Meyer R, et al. Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma. Leuk lymphoma. 2006;47(5):865–9.

    Article  CAS  PubMed  Google Scholar 

  91. Audigé A, Urosevic M, Schlaepfer E, et al. Anti-HIV state but not apoptosis depends on IFN signature in CD4+ T cells. J Immunol. 2006;177(9):6227–37.

    Article  PubMed  Google Scholar 

  92. Perry A, Vincent BJ, Parker SR. Intralesional corticosteroid therapy for primary cutaneous B-cell lymphoma. Br J Dermatol. 2010;163(1):223–5.

    CAS  PubMed  Google Scholar 

  93. Burg G, Dummer R, Kerl H. Classification of cutaneous lymphomas. Dermatol Clin. 1994;12(2):213–7.

    CAS  PubMed  Google Scholar 

  94. Wong KC, Weller PA. Primary cutaneous B cell lymphoma: outcomes and treatment. Australas J Dermatol. 1998;39(4):261–4.

    Article  CAS  PubMed  Google Scholar 

  95. Heinzerling L, Dummer R, Kempf W, Schmid MH, Burg G. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Arch Dermatol. 2000;136(3):374–8.

    Article  CAS  PubMed  Google Scholar 

  96. Kyrtsonis MC, Siakantaris MP, Kalpadakis C, et al. Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab. Eur J Haematol. 2006;77(4):300–3.

    Article  CAS  PubMed  Google Scholar 

  97. Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol. 2005;52(5):847–53.

    Article  PubMed  Google Scholar 

  98. Gitelson E, Al-Saleem T, Millenson M, Lessin S, Smith MR. Cutaneous B-cell lymphoma responds to rituximab: a report of five cases and a review of the literature. Leuk lymphoma. 2006;47(9):1902–7.

    Article  CAS  PubMed  Google Scholar 

  99. Heinzerling LM, Urbanek M, Funk JO, et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer. 2000;89(8):1835–44.

    Article  CAS  PubMed  Google Scholar 

  100. Farkas A, Kemeny L, French LE, Dummer R. New and experimental skin-directed therapies for cutaneous lymphomas. Skin Pharmacol Physiol. 2009;22(6):322–34.

    Article  CAS  PubMed  Google Scholar 

  101. Coors EA, Schuler G, Von Den Driesch P. Topical imiquimod as treatment for different kinds of cutaneous lymphoma. Eur J Dermatol : EJD. 2006;16(4):391–3.

    CAS  PubMed  Google Scholar 

  102. Bogle MA, Riddle CC, Triana EM, Jones D, Duvic M. Primary cutaneous B-cell lymphoma. J Am Acad Dermatol. 2005;53(3):479–84.

    Article  PubMed  Google Scholar 

  103. Grange F, Wechsler J, Guillaume JC, et al. Borrelia burgdorferi-associated lymphocytoma cutis simulating a primary cutaneous large B-cell lymphoma. J Am Acad Dermatol. 2002;47(4):530–4.

    Article  PubMed  Google Scholar 

  104. Hofbauer GF, Kessler B, Kempf W, Nestle FO, Burg G, Dummer R. Multilesional primary cutaneous diffuse large B-cell lymphoma responsive to antibiotic treatment. Dermatology. 2001;203(2):168–70.

    Article  CAS  PubMed  Google Scholar 

  105. Kutting B, Bonsmann G, Metze D, Luger TA, Cerroni L. Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. J Am Acad Dermatol. 1997;36(2):311–4.

    Article  CAS  PubMed  Google Scholar 

  106. Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol : Off J Am Soc Clin Oncol. 2008;26(14):2258–63.

    Article  CAS  Google Scholar 

  107. Fenot M, Quereux G, Brocard A, Renaut JJ, Dreno B. Rituximab for primary cutaneous diffuse large B-cell lymphoma-leg type. Eur J Dermatol : EJD. 2010;20(6):753–7.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This research was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.

Author information

Authors and Affiliations

  1. Department of Medicine, Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Meenal Kheterpal, Pooja Virmani & Patricia L. Myskowski

  2. Memorial Sloan Kettering Cancer Center, 500 Westchester Ave, West Harrison, NY, 10604, USA

    Meenal Kheterpal

  3. Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Neha Mehta-Shah, Alison Moskowitz & Steven M. Horwitz

  4. Memorial Sloan Kettering Cancer Center, 1233 York Avenue, New York, NY, 10065, USA

    Neha Mehta-Shah & Steven M. Horwitz

  5. 16 E60th Street, New York, NY, 10022, USA

    Pooja Virmani & Patricia L. Myskowski

  6. 1275 York Avenue, New York, NY, 10065, USA

    Alison Moskowitz

Authors
  1. Meenal Kheterpal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neha Mehta-Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pooja Virmani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Patricia L. Myskowski
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alison Moskowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Steven M. Horwitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven M. Horwitz.

Ethics declarations

Conflict of Interest

Meenal Kheterpal, Neha Mehta-Shah, Pooja Virmani, and Patricia L. Myskowski each declare no potential conflicts of interest.

Alison Moskowitz reports grants from Seattle Genetics.

Steven M. Horwitz reports grants and personal fees from Celgene, Seattle Genetics, Takeda Millennium, and Spectrum.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on B-cell NHL, T-cell NHL, and Hodgkin Lymphoma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kheterpal, M., Mehta-Shah, N., Virmani, P. et al. Managing Patients with Cutaneous B-Cell and T-Cell Lymphomas Other Than Mycosis Fungoides. Curr Hematol Malig Rep 11, 224–233 (2016). https://doi.org/10.1007/s11899-016-0322-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-016-0322-5

Keywords

Search

Navigation